Every material Form 8-K Medtronic has filed with the SEC since November 18, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medtronic said on October 15, 2026 that its exchange offer for MiniMed Group shares had settled and the separation was complete. The offer was 5.4 times subscribed, and Medtronic exchanged its remaining 252,813,348 MiniMed shares, ending its ownership stake in MiniMed. The same filing reports shareholder approval of all six AGM proposals and a leadership expansion for Michael Marinaro, with a base salary of $1,000,000 for fiscal 2027.
Exchange offer settled October 15, 2026; Medtronic exchanged all remaining interest, 252,813,348 MiniMed shares, and the offer was 5.4 times subscribed
Michael Marinaro appointed President, Medtronic, effective October 14, 2026, with oversight of Greater China operations; base salary set at $1,000,000 for fiscal 2027
Supplemental fiscal 2027 long-term incentive awards with an aggregate target value of approximately $3.25 million, to be granted November 2, 2026
All twelve director nominees were elected at the October 15, 2026 Annual General Meeting, and all six proposals passed
Medtronic filed an 8-K on September 17, 2026 to correct a typographical error in the prospectus for its exchange offer of MiniMed Group common stock for Medtronic ordinary shares. The prospectus had stated that a notice of guaranteed delivery would expire at 12:00 midnight, New York City time, while the corrected deadline is 5:00 p.m. New York City time on the second NYSE trading day after the notice is executed. Shareholders who plan to use guaranteed delivery need to meet the corrected deadline.
Medtronic commenced the exchange offer on September 14, 2026, for up to 225,361,295 newly issued MiniMed common shares.
The guaranteed delivery deadline is corrected to 5:00 p.m. New York City time on the second NYSE trading day after execution of the notice.
If the offer is oversubscribed, Medtronic currently intends to accept additional shares not exceeding two percent of total outstanding Medtronic ordinary shares.
Shareholders should read the Prospectus; D.F. King & Co., Inc. is the information agent at (877) 361-7972.
Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and GAAP diluted EPS of $1.14 versus $0.81 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75% and its non-GAAP diluted EPS guidance to $5.94 to $6.00, both measures improving on the prior outlook.
Q1 revenue of $9.756 billion, up 13.7% as reported and organically; the extra fiscal week benefited organic growth by approximately $570 million, per the company
Q1 GAAP diluted EPS of $1.14, up 40.7%; non-GAAP diluted EPS of $1.45, up 15.1%
FY27 organic revenue growth guidance raised to 7.25% to 7.75% from 6.75% to 7.25%
FY27 non-GAAP diluted EPS guidance raised to $5.94 to $6.00 from $5.90 to $6.00
Medtronic reported fiscal 2026 revenue of $36.4 billion, up 8.4% as reported and 5.8% organic, and fourth-quarter revenue of $9.8 billion, up 9.9%. Fiscal 2026 non-GAAP diluted EPS rose 0.7% to $5.53, while non-GAAP operating margin fell 130 basis points, and fourth-quarter non-GAAP diluted EPS fell 4.3% to $1.55. The company guided fiscal 2027 non-GAAP diluted EPS to $5.90 to $6.00 and raised its quarterly dividend to $0.72 per share.
Q4 revenue was $9.807 billion, up 9.9% as reported and 6.6% organic.
Q4 GAAP diluted EPS was $0.96, up 17.1%; non-GAAP diluted EPS was $1.55, down 4.3%.
FY27 guidance calls for organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS of $5.90 to $6.00.
Quarterly dividend raised to $0.72 per share, payable July 17, 2026, to holders of record on June 26, 2026.
Medtronic said Brett Wall is leaving his role as Executive Vice President and President, Neuroscience Portfolio, and that Dr. Kweli Thompson will take over the role effective June 1, 2026. Mr. Wall will stay on as an employee until September 1, 2026 to help with the transition and will receive severance under the company's executive practices. The change is a leadership transition for one of Medtronic's business portfolios, and the filing contains no financial results or guidance.
Brett Wall departs as Executive Vice President and President, Neuroscience Portfolio
Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, takes over the Neuroscience role effective June 1, 2026
Mr. Wall remains an employee until September 1, 2026 to assist with the transition
Severance follows practices described in the 2025 Proxy Statement filed August 25, 2025
Medtronic said an unauthorized third party accessed data in certain of its corporate IT systems and that it has contained the incident with outside cybersecurity experts. The company said it has found no impact to products, patient safety, manufacturing, financial reporting systems or its ability to meet patient needs, and does not currently expect a material effect on its business or financial results.
Unauthorized party accessed data in certain Medtronic corporate IT systems; disclosed April 24, 2026.
Company has identified no impact to products, patient safety, manufacturing and distribution, or financial reporting systems.
Medtronic is working to identify any personal information that may have been accessed and will notify individuals as needed.
Company does not currently expect a material impact on its business or financial results.
Medtronic lowered its fiscal 2026 non-GAAP EPS guidance to $5.50 to $5.54, down from $5.62 to $5.66 given on its Q3 earnings call. The cut reflects a $157 million one-time MiniMed charge tied to Blackstone payments and dilution from the March 9, 2026 MiniMed IPO, which together hit fourth-quarter results. Fiscal 2027 high single-digit EPS growth guidance was left unchanged.
FY2026 non-GAAP EPS guidance now $5.50 to $5.54, versus $5.62 to $5.66 previously
One-time $157 million MiniMed charge expected in Q4 FY2026, about $0.08 per share impact
IPO of 10% of MiniMed closed March 9, 2026, with about $0.04 per share dilution in Q4 FY2026
FDA cleared the MiniMed Flex insulin pump on March 18, 2026, several months earlier than anticipated
Medtronic reported fiscal third-quarter 2026 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, but GAAP diluted EPS fell to $0.89 from $1.01 a year earlier and non-GAAP diluted EPS fell to $1.36 from $1.39. The company reiterated its FY26 organic revenue growth of about 5.5% and non-GAAP diluted EPS guidance of $5.62 to $5.66, so shareholders see sales growth alongside lower profit per share in the quarter.
Q3 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidance
GAAP diluted EPS of $0.89 vs. $1.01 a year earlier; non-GAAP diluted EPS of $1.36 vs. $1.39
Cardiovascular Portfolio revenue of $3.457 billion, up 13.8%; Cardiac Ablation Solutions revenue up 80%
FY26 guidance reiterated: organic revenue growth of about 5.5% and non-GAAP diluted EPS of $5.62 to $5.66, including a potential tariff impact of about $185 million
Medtronic reported second quarter fiscal 2026 results for the period ended October 24, 2025, with revenue of $8.961 billion and GAAP diluted EPS of $1.07, both up year over year. The company also raised its fiscal 2026 organic revenue growth and adjusted EPS guidance, which matters to shareholders because it signals higher expected earnings for the full year.
Revenue of $8.961 billion rose 6.6% as reported and 5.5% organic; Cardiac Ablation Solutions revenue increased 71%.
GAAP diluted EPS was $1.07, up 8%; non-GAAP diluted EPS was $1.36, also up 8%.
FY26 organic revenue growth guidance raised to approximately 5.5% from approximately 5.0%.
FY26 diluted non-GAAP EPS guidance set at $5.62 to $5.66, versus the prior $5.60 to $5.66, including a potential tariff impact of approximately $185 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medtronic filing is on SEC EDGAR ↗. 8-K briefs of other companies →